On January 5, 2022 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, reported that they are scheduled to deliver a corporate presentation at the following virtual conferences (Press release, Autolus, JAN 5, 2022, https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-present-conferences-during-january-2022 [SID1234598254]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Lucinda Crabtree, Senior Vice President, Finance, will present at the H.C. Wainwright BioConnect Conference, where an on-demand webcast will be available on Monday, January 10, 2022, starting at 7.00 am ET.

Dr. Christian Itin, Chief Executive Officer, will present at the 40th annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 8.15 am ET.
Senior management will participate in virtual one-on-one meetings with investors at both conferences.

The presentations will be available on the investor relations section of Autolus’ website at View Source An archived replay will be available on the company’s website for a period of 90 days after the conferences.